Physicians and biologists here present their experimental work in the field of hyperthermia, paying particular regard to its relevance in clinical situations. Principles of heat action and combined treatment modalities are explicated. The main topics discussed are the effects of such treatment on normal tissues, animal tumors, malignant cell lines and human tumors.

Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology."

Biologists and radiotherapists present their experimental work and clinical data in the field of radiation injuries of normal tissues and organs. Particular regard is payed to the relevance of biological mechanisms in clinical situations. Principles of radiation damage and combined treatment toxicity in radio-chemotherapy are being explained. The main topics discussed are the importance of microvasculature, time, doseand fractionation and factors modifying clinical radioresponse for early andlate radiation effects. Tissues and organs considered in this volume are mucosa and skin, lung and heart, bladder and muscle, CNS and eye. Special problems of pediatric radiotherapy, TBI, IORT and second malignacies are also mentioned.

I Anatomie, AEtiologie, Epidemiologie und Molekularbiologie.- 1 Anatomie und Physiologie der Lunge.- 2 AEtiologie und Epidemiologie.- 3 Molekulargenetische Aspekte, Tumorbiologie und Mechanismen der Metastasierung.- II Vorsorge und Fruherkennung.- 4 Neue Aspekte der Fruherkennung und des lokalen Stagings.- III Diagnostik, Pathologie und Stadieneinteilung.- 5 Diagnosesicherung und pratherapeutische Diagnostik.- 6 Endoskopische Diagnostik.- 7 Radiologische Diagnostik des Bronchialkarzinoms - Projektionsradiographie und Computertomographie.- 8 Magnetresonanztomographie.- 9 Positronenemissionstomographie (PET).- 10 Tumor-Marker - Bedeutung fur Diagnostik und Verlaufskontrolle.- 11 Pathologie, Klassifikation und Stadieneinteilung.- IV Therapie.- 12 Geschichte der Behandlung der Lungenkarzinome.- 13 Nichtkleinzellige Lungenkarzinome.- 14 Kleinzellige Lungenkarzinome.- 15 Bronchuskarzinoid.- 16 Seltene Lungentumoren.- 17 Therapie isolierter Metastasen.- 18 Tumorbedingte Komplikationen.- 19 Therapiebedingte Komplikationen und Spatfolgen nach Operation, Radio- und Chemotherapie.- V Nachsorge und Prognose.- 20 Nachsorge und Rehabilitation.- 21 Psychoonkologie und Lebensqualitat.- 22 Chemopravention.- VI Zukunftsperspektiven.- 23 Videoassistierte Thoraxchirurgie (VATS) - Weiterentwicklung, robotergesteuerte Therapie.- 24 Verbesserung der Strahlentherapie bei der Behandlung des Lungen- karzinoms.- 25 Neue therapeutische Ansatze in der internistischen Therapie nicht- kleinzelliger Lungenkarzinome.- 26 Molekulare Prognosefaktoren.